Winton Group’s AbCellera Biologics ABCL Stock Holding History

Winton Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$442K	Buy	+56,300	New	+$275K	0.01%	746
2023 Q3	–	Sell	-17,247	Closed	-$111K	–	758
2023 Q2	$111K	Buy	+17,247	New	+$118K	0.01%	711

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Winton Group's ABCL Position: Q2 2026 in Review

Winton Group opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 56,300 shares worth $442K. The stake represents 0.01% of the portfolio and ranks #746 among its holdings. This is a return to the name: Winton Group previously reported a position in ABCL as recently as Q2 2023.

Winton Group first reported a position in ABCL in Q2 2023 and has held it in 2 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Winton Group held 56,300 shares of AbCellera Biologics worth $442K as of Q2 2026.
AbCellera Biologics was a new Winton Group position in Q2 2026.
AbCellera Biologics made up 0.01% of Winton Group's portfolio in Q2 2026, its #746 holding.
Winton Group first reported a position in AbCellera Biologics in Q2 2023 and has held it in 2 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.